Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: A 2-year follow-up

International Urogynecology Journal

Volumn 19, Issue 7, 2008, Pages 905-909

  Kuschel, Stefanie ^a   Werner, Matthias ^b   Schmid, Daniel Max ^b   Faust, Elke ^a   Schuessler, Bernhard ^a  

^a LUZERNER KANTONSSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Botox; Botulinum toxin; Intradetrusoral injections; Intravesical injection; Nonneurogenic; Overactive bladder

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; SOLIFENACIN;

ADULT; AGED; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTOMETRY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STRESS INCONTINENCE; TRANSVAGINAL SLING; TREATMENT DURATION; URODYNAMICS;

EID: 44649190496     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00192-007-0548-9     Document Type: Article

References (25)

1. Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 61:37-49
2. Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review. BMJ 326:841-844
3. Chapple CR, Rechberger T, Al-Shukri S et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303-310
4. Hay-Smith J, Herbison P, Ellis G, Moore K (2002) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev:CD003781
5. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K (2006) Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. BMJ 332:455-459
6. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692-697
7. Werner M, Schmid DM, Schussler B (2005) Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study. Am J Obstet Gynecol 192:1735-1740
8. Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176:177-185
9. Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: An initial experience. Urology 63:1071-1075
10. Sahai A, Khan MS, Fowler C, Dasgupta P (2005) Botulinum toxin: A new dimension in the treatment of lower urinary tract dysfunction. Urology 65:211
11. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:984-989
12. Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510-515
13. Rajkumar GN, Small DR, Mustafa AW, Conn G (2005) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96:848-852
14. de Miguel F, Chancellor MB (2006) Pittsburgh experience with botulinum toxin A injection. Actas Urol Esp 30:310-314
15. Riccabona M, Koen M, Schindler M et al (2004) Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171:845-848 discussion 848
16. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104:1374-1379
17. Rapp DE, Turk KW, Bales GT, Cook SP (2006) Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175:1138-1142
18. Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107:125-133
19. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB (2004) Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172:1529-1532
20. MacKenzie I, Burnstock G, Dolly JO (1982) The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7:997-1006
21. Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977-982 discussion 982-983
22. Cockayne DA, Hamilton SG, Zhu QM et al (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407:1011-1015
23. Khera M, Somogyi GT, Salas NA, Kiss S, Boone TB, Smith CP (2005) In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology 66:208-212
24. Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644-650
25. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528-535